Session » (1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention
- 9:00AM-11:00AM
-
Abstract Number: 1531
A Retrospective Analysis of the Efficacy of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): A TriNetX Database Study
- 9:00AM-11:00AM
-
Abstract Number: 1527
Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients
- 9:00AM-11:00AM
-
Abstract Number: 1525
Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1517
Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients
- 9:00AM-11:00AM
-
Abstract Number: 1518
Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 1526
Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study
- 9:00AM-11:00AM
-
Abstract Number: 1520
Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method
- 9:00AM-11:00AM
-
Abstract Number: 1528
Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
- 9:00AM-11:00AM
-
Abstract Number: 1533
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
- 9:00AM-11:00AM
-
Abstract Number: 1521
Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1529
Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
- 9:00AM-11:00AM
-
Abstract Number: 1530
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
- 9:00AM-11:00AM
-
Abstract Number: 1515
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1514
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
- 9:00AM-11:00AM
-
Abstract Number: 1519
Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1532
Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis
- 9:00AM-11:00AM
-
Abstract Number: 1516
Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity
- 9:00AM-11:00AM
-
Abstract Number: 1524
The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis
- 9:00AM-11:00AM
-
Abstract Number: 1523
The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1522
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
- 9:00AM-11:00AM
-
Abstract Number: 1513
Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019